Autoantibody

Vera Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 22, 2022
Degenerative disease, IgA nephropathy, Vera, BK virus, Autoantibody, Therapy, B-cell activating factor, Patient, Virus, Immunoglobulin A, Standard of care, Lupus nephritis, B cell, Calendar, BK, Polyomaviridae, Online shopping, Vaccine

A replay of the presentations will be available for 90 days and can be accessed by visiting the Investor Calendar section of the Vera Therapeutics website.

Key Points: 
  • A replay of the presentations will be available for 90 days and can be accessed by visiting the Investor Calendar section of the Vera Therapeutics website.
  • Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases.
  • Veras mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients.
  • In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful.

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

Retrieved on: 
Thursday, November 17, 2022
COVID-19, Degenerative disease, Diagnosis, ASN, American Society of Nephrology, BYU College of Life Sciences, Immunoglobulin A, FRCP, BK virus, Union, ESRD, Food, University, Autoantibody, Dialysis, Radar, Therapy, College, B-cell activating factor, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, TACI, Clinical trial, Cytokine, Biomarker, Surrogate, Coagulation, Chronic kidney disease, Standard of care, University of Leicester, Lupus nephritis, Society, International, Security (finance), B cell, Barratt, Research, BK, Kidney failure, Polyomaviridae, KOL, Vera, Pharmaceutical industry, Vaccine, IgA nephropathy

BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host a key opinion leader (KOL) webinar on IgA nephropathy (IgAN), a common cause of kidney failure. The webinar will be held on Monday, November 28, 2022 at 2:00pm ET.

Key Points: 
  • Recent data presented by Dr. Barratt at the American Society of Nephrology (ASN) Kidney Week 2022 showed atacicept reduced immune complex levels in patients with IgAN.
  • In addition, the Vera Therapeutics leadership team will provide an overview of the ongoing Phase 2b ORIGIN trial of atacicept in IgAN and the Companys pipeline.
  • If the data from the ORIGIN trial are supportive, Vera Therapeutics expects to initiate a pivotal Phase 3 clinical trial of atacicept in 2023.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.

Amber Specialty Pharmacy Selected to Dispense TZIELD™ (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages 8 Years and Older with Stage 2 Type 1 Diabetes

Retrieved on: 
Monday, November 21, 2022
Diabetes, Pharmaceutical, Health, ACHC, National Association, T1D, Specialty pharmacy, Autoantibody, Child, Person, Accreditation Commission for Health Care, Pharmacy, URAC, Patient, Hospital

Amber Specialty Pharmacy announces that it will begin dispensing TZIELD (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D.

Key Points: 
  • Amber Specialty Pharmacy announces that it will begin dispensing TZIELD (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D.
  • Living with or caring for a child with T1D requires constant daily management, said Kristin Williams, president of Amber Specialty Pharmacy.
  • Amber Specialty Pharmacy has built an exceptional reputation by providing personalized support and quality clinical care to patients and families.
  • Amber Specialty Pharmacy was named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy.

Feinstein Institutes lupus researchers recognized with top honors

Retrieved on: 
Thursday, November 17, 2022
Research, Hospitals, Other Health, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Science, Other Science, Diamond, Medicine, Behavior, NAS, Brain, Autoimmune disease, Lupus, Friends, Molecular medicine, Hofstra University, Feinstein Institute for Medical Research, DRS, Medical research, American College of Rheumatology, Multimedia, American College, Donald, National academy, Science, Doctor of Philosophy, Autoantibody, Cancer, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Maureen, Research, MBBS, Degenerative disease, Northwell Health, ACR, Inflammation, Master, Genetics, Mental health, National Academy of Sciences, Autoimmunity, Education, Weatherall Institute of Molecular Medicine, College, Cognition, Hope, Patient, Antibody, Management, Pharmaceutical industry, Rheumatology, MD

Anne Davidson (left) and Betty Diamond received top honors from the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals.

Key Points: 
  • Anne Davidson (left) and Betty Diamond received top honors from the American College of Rheumatology (ACR) and the Association of Rheumatology Professionals.
  • Dr. Diamond is the director of the Institute of Molecular Medicine at the Feinstein Institutes and a pioneer in the basic science research of autoimmune diseases, particularly systemic lupus erythematosus.
  • The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State.
  • Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine.

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

Retrieved on: 
Wednesday, November 16, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Inflammatory bowel disease, Clinical trial, Friends, Diplopia, Cell, TED, Menstrual disorder, Headache, Autoantibody, Safety, Disease, Hair, Huber loss, Breathe Me, Fibroblast, European Group, Week, Partnership, PMDA, Science, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hyperglycemia, Pain, Grit, COVID-19, Health, Hope, Diarrhea, Incidence, Patient, FDA, Trial of the century, Blood pressure, Pressure, Autoimmunity, Spasm, Swelling, Medicines and Healthcare products Regulatory Agency, Cover My Eyes (Pain and Heaven), Red, Graves' ophthalmopathy, Diabetes, Food, Fatigue, Courage, Tachycardia, Medicine, Myalgia, OPTIC, Inflammation, Nausea, Exophthalmos, Family, IBD, Pharmaceutical industry, Silviculture, Medical device, Medical imaging, Birth control, Dysgeusia

With this trial, we hope to explore the role that TEPEZZA could have for Japanese patients struggling with active Thyroid Eye Disease.

Key Points: 
  • With this trial, we hope to explore the role that TEPEZZA could have for Japanese patients struggling with active Thyroid Eye Disease.
  • The trial methodology is based on the OPTIC Phase 3 trial conducted in the United States and Europe.
  • We are so grateful for the participation and partnership of those living with Thyroid Eye Disease in Japan and our principal investigators, said Elizabeth H.Z.
  • The need for a non-surgical, non-steroidal treatment option for Thyroid Eye Disease in Japan is significant.

Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, IgA nephropathy, Private Securities Litigation Reform Act, Vera, Autoantibody, Viremia, U.S. Securities and Exchange Commission, Immunosuppression, Annual general meeting, Nasdaq, COMPASS, B cell, Cytokine, Society, BKV, Virus, Immunoglobulin A, B-cell activating factor, Coagulation, Disease, Mortality, Therapy, Chronic kidney disease, Lupus nephritis, Degenerative disease, Safety, BK virus, Proteinuria, Biomarker, Program, Polyomaviridae, Clinical trial, Standard of care, ASN, Patient, American Society of Nephrology, Pfizer, CEO, TACI, Infection, Security (finance), Kidney failure, Quarter, COVID-19, Bank, Pharmaceutical industry, Vaccine, BK

During the third quarter of 2022, we continued to make progress advancing our late-stage clinical pipeline of atacicept and MAU868, said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics.

Key Points: 
  • During the third quarter of 2022, we continued to make progress advancing our late-stage clinical pipeline of atacicept and MAU868, said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics.
  • IgAN is a common cause of kidney failure and there is a high unmet medical need for treatment of IgAN globally.
  • We are also pleased to announce initiation of our pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis.
  • Vera reported $114.4 million in cash, cash equivalents, and marketable securities as of September 30, 2022.

ValenzaBio Announces Positive Preliminary Data from Phase 1b/2a Trial of VB119, an Anti-CD19 Monoclonal Antibody for the Treatment of Primary Membranous Nephropathy

Retrieved on: 
Thursday, November 3, 2022
FDA, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Glomerulonephritis, Therapy, Time, Serum, Society, PMN, Safety, Abstract, Poster, Autoantibody, CD19, Urine, ASN, B cell, Microdeletion syndrome, A2, American Society of Nephrology, Disease, Mab, Autoimmunity, Proteinuria, Patient, Pharmacokinetics, Vaccine, Pharmaceutical industry

These data represent the first clinical proof-of-concept for an anti-CD19 antibody in this disease and demonstrate potential differentiation from other therapies used in this indication.

Key Points: 
  • These data represent the first clinical proof-of-concept for an anti-CD19 antibody in this disease and demonstrate potential differentiation from other therapies used in this indication.
  • PMN, also known as idiopathic membranous nephropathy, is an autoimmune glomerular disease and is one of the leading causes of non-diabetic nephrotic syndrome.
  • Available treatment regimens fail to achieve complete remission in most patients with primary membranous nephropathy.
  • The company is advancing a pipeline of differentiated monoclonal antibodies with best-in-class properties, targeting clinically validated mechanisms of action, to provide improved treatment options for patients.

Labroots Announces 13th Annual Clinical Diagnostics & Research Virtual Event to be held on November 9th, 2022

Retrieved on: 
Thursday, November 3, 2022
Pathology, PCR, Medical laboratory, Monkeypox, Solution, Melissa Chaty, Risk, COVID-19, Time, Autoantibody, SUC, Research, Monkeypox virus, Science Publishing Group, Drug resistance, Method, ART, QIAGEN, Labroots, IIM, Science, Learning, University of Toronto, Classification, LR, Mount Sinai Hospital, Assistant professor, Social, Environment, Thermo Fisher Scientific, University, Q&A, Severe acute respiratory syndrome coronavirus 2, Precision medicine, Medical device, Pharmaceutical industry, Vaccine, Online shopping, News, Facebook, Clinical

YORBA LINDA, Calif., Nov. 3, 2022   /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, today announced its 13th annual Clinical Diagnostics & Research virtual event. On November 9th, an audience comprised of clinicians, research scholars, top scientists, academia and industry professionals and pharma and biotech will gather under a virtual roof to learn from recognized speakers driving innovation in diagnostics and precision medicine.

Key Points: 
  • Leading experts will explore advancements and new technologies in clinical diagnosis for early disease detection, treatment and prevention during this free, online event
    YORBA LINDA, Calif., Nov. 3, 2022 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual events and webinars, today announced its 13th annual Clinical Diagnostics & Research virtual event.
  • For over a decade, this online event has served as a premier meeting place for the clinical diagnostics, research and laboratory medicine communities.
  • And, once again Labroots' Clinical Diagnostics & Research 2022 will deliver on its commitment of breaking science in the areas of emerging diagnostic technologies, perspectives on SARS-CoV-2 and Monkeypox, precision medicine and special populations, and the lab's role in advancing equity.
  • Now, Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 202

Retrieved on: 
Monday, October 17, 2022
Securities and Exchange Commission (Philippines), BK virus, B-cell activating factor, Therapy, Polyomaviridae, BKV, IgA nephropathy, Cytokine, BK, Degenerative disease, Society, Barratt, Patient, FRCP, Standard of care, Pfizer, Security (finance), B cell, Nephrology, Lupus nephritis, University, Autoantibody, Virus, Private Securities Litigation Reform Act, Biomarker, Vera, Immunosuppression, Immunoglobulin A, TACI, Coagulation, COVID-19, University of Leicester, Vaccine

BK Virus is a polyoma virus that can be reactivated in settings of immunosuppression, such as in kidney transplant.

Key Points: 
  • BK Virus is a polyoma virus that can be reactivated in settings of immunosuppression, such as in kidney transplant.
  • It is a leading cause of kidney transplant loss and transplant-associated morbidity; there are currently no approved treatments for BKV.
  • Vera holds an exclusive worldwide license from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for the development and commercialization of MAU868 in all indications.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.

Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Pharmaceutical, Optical, General Health, Health, FDA, Clinical Trials, Other Health, Pressure, Physician, LinkedIn, Spasm, Fibroblast, Breathe Me, Disease, Medicine, Diabetes, Nausea, Fatigue, Menstrual disorder, Graves' ophthalmopathy, Science, TED, Inflammatory bowel disease, Myalgia, FACP, Patient, Diarrhea, Courage, Tachycardia, Research, Twitter, Instagram, Cell, Blood pressure, Severe cognitive impairment, Hair, Nasdaq, Red, Grit, Hyperglycemia, Autoantibody, ATA, Headache, Swelling, Pain, Incidence, IBD, European Group, Lists of World Heritage Sites, Autoimmunity, Inflammation, Health, FDA, Exophthalmos, Huber loss, American Thyroid Association, Pharmaceutical industry, Vaccine, Medical device, Medical imaging, Birth control, Facebook, Dysgeusia

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.
  • We look forward to bringing these important data to the forefront to help physicians better understand the condition for their patients.
  • Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA.
  • Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD).